Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | PI4KA | P42356 | 2/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29873925 | 1.00 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL3328527 | 0.90 | PDPK1 (0.54) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL533603 | 0.79 | PDPK1 (0.44) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.78 | PDPK1 (0.96) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL2997392 | 0.76 | DPP4 (0.61) | PDPK1GDAXDHCDK2DPP4 | |
| SCHEMBL16146853 | 0.76 | PDPK1 (0.41) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL612211 | 0.76 | GDA (0.41) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| EP-2097430-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[N- ACYL)AMIDOSELENOPHOSPHATE-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2009-09-09 | — | — | EP | claimed |
| WO-2009005382-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2009-01-08 | — | — | WO | claimed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | claimed |
| WO-2008048128-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[(N- ACYL)AMIDOSELENOPHOSPHATE]-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2008-04-24 | — | — | WO | claimed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | claimed |
| EP-0533825-B1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | UNIV WAKE FOREST (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | claimed |
| EP-0533825-A4 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | — | 1993-06-02 | — | — | EP | claimed |
| EP-0533825-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES. | UNIV WAKE FOREST (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1991019726-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | WAKE FOREST UNIVERSITY (US) | 1991-12-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885GDA 1170/4885PI4KA 2349/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885PI4KA 2483/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885PI4KA 2752/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885PI4KA 2752/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885PI4KA 2483/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | PDPK1 593/4885GDA 770/4885PI4KA 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.